Recent Analyst Stock Rating News
The Best Trading Research Platform
For Retail Investors and Professional Trades Alike.Get Started for Free
Narumi Nakagiri is an analyst at Daiwa Capital. Analyst ratings are quantitative and qualitative analysis of a stock by Wall Street stock rating analysts. Stock ratings consist of expected future growth, current stock valuation and macroeconomic trends. Updated 03/27/2025
| Buy Now | Get Alert | |||||||||
|---|---|---|---|---|---|---|---|---|---|---|
| 08/16/2024 | ILMN | Buy Now | Illumina | $82.28 | 87.17% | Narumi Nakagiri23% | $120 → $154 | Upgrade | Neutral → Buy | Get Alert |
| 08/08/2024 | PFE | Buy Now | Pfizer | $25.02 | 35.89% | Narumi Nakagiri23% | $28 → $34 | Upgrade | Neutral → Outperform | Get Alert |
| 07/23/2024 | JNJ | Buy Now | Johnson & Johnson | $163.20 | -8.09% | Narumi Nakagiri23% | $160 → $150 | Downgrade | Outperform → Neutral | Get Alert |
| 12/21/2023 | AMGN | Buy Now | Amgen | $304.52 | 5.08% | Narumi Nakagiri23% | → $320 | Upgrade | Neutral → Buy | Get Alert |
| 11/02/2023 | BMY | Buy Now | Bristol-Myers Squibb | $58.97 | -8.43% | Narumi Nakagiri23% | $68 → $54 | Downgrade | Outperform → Neutral | Get Alert |
| 05/11/2023 | PFE | Buy Now | Pfizer | $25.02 | 51.88% | Narumi Nakagiri23% | $51 → $38 | Downgrade | Outperform → Neutral | Get Alert |
| 02/07/2023 | PFE | Buy Now | Pfizer | $25.02 | 103.84% | Narumi Nakagiri23% | → $51 | Upgrade | Neutral → Outperform | Get Alert |
| 07/07/2022 | MRK | Buy Now | Merck & Co | $87.95 | 15.97% | Narumi Nakagiri23% | $89 → $102 | Upgrade | Hold → Outperform | Get Alert |
| 12/16/2021 | MRK | Buy Now | Merck & Co | $87.95 | -20.41% | Narumi Nakagiri23% | → $70 | Initiates | → Neutral | Get Alert |
| 09/23/2021 | AMGN | Buy Now | Amgen | $304.52 | -27.76% | Narumi Nakagiri23% | → $220 | Downgrade | Outperform → Neutral | Get Alert |
